A cost‑effectiveness and budget impact analysis of first‑line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany mydrg.de

A cost‑effectiveness and budget impact analysis of first‑line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

• B.S.
• Montag, 11.04.2016

A cost‑effectiveness and budget impact analysis of first‑line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany (Springer).

A04.7 - Arzneimittel - Kosten-Nutzen - Kostenvergleich - Krankenhausbehandlung - Nosokomiale Infektionen - URL

« Grundseminar für Kodierkräfte | A cost‑effectiveness and budget impact analysis of first‑line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany | Avenir (Groupe Mutuel) verweigere Kostenübernahme für günstigere Therapie »